Takeda Pharmaceutical Co. Ltd.’s HyQvia (immune globulin infusion 10% [human]/recombinant human hyaluronidase) was approved by the US Food and Drug Administration for chronic inflammatory demyelinating polyneuropathy (CIDP), a rare disorder. The Japanese drug maker may soon find itself neck-and-neck in competition, however, against an up-and-coming European biotech company that produced positive data for a drug in the same disease last year.
How much of a market CIDP represents overall remains tough to tease out due to challenges with diagnosing the disease.
